Skip to Main Content

About Terumo Cardiovascular

Member of a cardiac surgery team

We’re part of your team.

At Terumo Cardiovascular, we develop, manufacture and distribute medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. This includes a full-line of perfusion products, endoscopic vessel harvesting products and surgical stabilization products.

Our mission is to work as a team to save one more life, today and every day. We do this by providing lifesaving technology to cardiac surgery teams around the world.

Terumo Cardiovascular — and all Terumo companies — embody Terumo Corporation’s commitment to bring revolutionary advances to the frontlines of healthcare. Our global associates constantly seek innovation and take on new challenges to positively impact healthcare around the world.

Terumo was founded in 1921 by a group of medical scientists led by Dr. Shibasaburo Kitasato, for the purpose of manufacturing reliable clinical thermometers in Japan. For over a century, Terumo has continued to contribute to society through healthcare. Today, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Learn Moreexternal link icon

Our History

In 1999, Terumo Corporation merged three of the most established and trusted brands in perfusion products — CAPIOX®, Sarns™ and CDI® — to create Terumo Cardiovascular Systems. The company inherited a rich history that stretches back to the pioneering years of open-heart surgery.

Since 1999, Terumo Cardiovascular has expanded its cardiac surgery product line to include vascular grafts, endoscopic vessel harvesting, and more.

Terumo Corporation, Terumo Cardiovascular’s parent company, spans an even greater time period in medical device development. Its first product, a clinical thermometer, was developed in the early 1920s. It has continued to grow and is now one of the largest medical device manufacturers in the world. Visit Terumo Corporation’s website to view their full history.

Today, in virtually every cardiac surgery center around the world, heart teams choose products made by Terumo Cardiovascular.

Timeline of Innovation

1921-2000

1921

The Sekisen Ken-onki is founded, eventually becoming Terumo Corporation

1922

Terumo Corporation introduced its first product — a clinical thermometer

1961

Dick Sarns delivers his first custom-made heart-lung machine

1963

Sarns, Inc. produced the S2000, its first modular heart-lung machine

1971

Terumo America Inc. and Terumo Europe S.A. were founded

1982

CAPIOX® II Oxygenator, the world’s first hollow fiber oxygenator, introduced

1984

Cardiovascular Devices Inc. (CDI) introduced the Gas Stat System, the industry’s first continuous monitor

1988

CAPIOX® E Oxygenator launched, offering venous gravity drainage and an arterial reservoir for ease-of-use

1992

Sarns, Inc. introduced the Sarns™ Modular Perfusion System 8000

1993

CAPIOX® SX Oxygenator launched

1998

CDI® Blood Parameter Monitoring System 500 introduced

1999

Terumo Corporation acquired the Sarns™ and CDI® brands from 3M and merged the technologies with CAPIOX® to form Terumo Cardiovascular Systems

Xcoating™, a non-heparin biocompatible coating, launched

2001-2010

2000

CAPIOX RX Oxygenator introduced

2001

Terumo Cardiovascular Systems entered into an exclusive distribution agreement with Pall Corporation for cardiovascular filters

2002

CAPIOX Baby RX™ (RX05) Neonatal Oxygenator launched

Terumo Corporation acquired Vascutek Ltd., a global leader in artificial vascular grafts

2003

Terumo® Advanced Perfusion System 1 introduced

2005

Terumo Corporation became number one in the global perfusion products market and began to expand its portfolio to new product categories in the cardiac operating room

VirtuoSaph™ Endoscopic Vein Harvesting System launched

2006

Terumo Cardiovascular Systems entered into an exclusive distribution agreement with Harvest Technologies Corporation to distribute SmartPrep® platelet gel therapy in the North American cardiovascular market

TLink™ Data Management System introduced

CAPIOX® RX15/25 Oxygenators launched in the United States, extending its offering of hollow-fiber oxygenators for use with all patients

2007

Terumo Cardiovascular Systems became the exclusive distributor of Vascutek® Vascular Grafts in the United States

2008

CAPIOX® FX Oxygenator, the industry’s first oxygenator with an integrated arterial filter, introduced

CAPIOX® FX05 Oxygenator, the industry’s first pediatric oxygenator with an integrated arterial filter, launched

2011-Present

2011

Terumo Corporation acquired Harvest Technologies Corporation, a leader in the development of point-of-care cell therapy

2012

Terumo Cardiovascular Group acquired the Orpheus™ Perfusion Simulation technology from Ulco Technologies

2013

Terumo Cardiovascular Group formed, creating a global headquarters focused on the needs of cardiac surgery teams worldwide. Terumo Cardiovascular Group acquired the beating heart and stabilization technologies from Estech Cardiothoracic Stabilization Technologies

2014

Terumo Cardiovascular Group became the exclusive distributor of Nonin Medical’s SenSmart™ Model X-100 in the United States

2016 CAPIOX® FX Advance Oxygenator introduced, further reducing prime volume and lowering hemodilution.
2018

510(k) clearance received for the CDI® Blood Parameter Monitoring System 550, adding new parameter for oxygen delivery.

2019

Capiox® NX19 Oxygenator with UltraPrime™ Technology introduced, Terumo’s smallest full-size adult oxygenator to date.

2019

Terumo Cardiovascular Group and Talis Clinical announced partnership to deliver intelligent, real-time guidances to CVOR and CVICU to improve outcomes.

2019 Terumo Cardiovascular Group and Hemostasis introduce BoneSeal® Bone Hemostat.
2020 Terumo Cardiovascular Group updates name to Terumo Cardiovascular and introduces new logo, to focus on its market and customers.